ClinicalTrials.Veeva

Menu

Radioembolization for Hepatocellular Carcinoma With Portal Vein Tumoral Thrombosis

S

Scientific Institute for Research Hospitalization and Healthcare (IRCCS)

Status

Completed

Conditions

Hepatocellular Carcinoma

Treatments

Radiation: yttrium-90 radioembolization

Study type

Observational

Funder types

Other

Identifiers

NCT04771988
Y90-2-LT-15-01

Details and patient eligibility

About

In patients with hgepatocellular carcinoma (HCC) and portal vein tumoral thrombosis (PVTT), Sorafenib represents the treatment of choice but more recently, trans-arterial radioembolization (TARE) with yttrium-90 has been also proposed. A considerable percentage of such patients are not only able to achieve stability of the disease, but also to obtain a complete radiological response (CR). The possibility of achieving a CR might allow these patients to be listed for liver transplantation (LT), in order to cure not only the cancer but also the underlying cirrhosis that generated it.

Enrollment

17 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. diagnosis of HCC;
  2. age ≥ 18 years;
  3. performance status according to Eastern Cooperative Oncology Group 0-1;
  4. preserved liver function (Child-Pugh score ≤B7);
  5. PVTT limited to the first order portal branch.

Exclusion criteria

  1. any contraindication to TARE treatment;
  2. macrovascular invasion extended to the main portal trunk and/or to the contralateral portal branch;
  3. presence of extra-hepatic disease

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems